AU2009249812B2 - Perfluorcarbon nanoemulsions with endocytosis enhancing surface for gene-transfer - Google Patents

Perfluorcarbon nanoemulsions with endocytosis enhancing surface for gene-transfer Download PDF

Info

Publication number
AU2009249812B2
AU2009249812B2 AU2009249812A AU2009249812A AU2009249812B2 AU 2009249812 B2 AU2009249812 B2 AU 2009249812B2 AU 2009249812 A AU2009249812 A AU 2009249812A AU 2009249812 A AU2009249812 A AU 2009249812A AU 2009249812 B2 AU2009249812 B2 AU 2009249812B2
Authority
AU
Australia
Prior art keywords
nanoemulsion
component
perfluorcarbon
gene
sirna
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2009249812A
Other languages
English (en)
Other versions
AU2009249812A1 (en
Inventor
Soren Schreiber
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Soluventis GmbH
Original Assignee
Soluventis GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Soluventis GmbH filed Critical Soluventis GmbH
Publication of AU2009249812A1 publication Critical patent/AU2009249812A1/en
Application granted granted Critical
Publication of AU2009249812B2 publication Critical patent/AU2009249812B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/40—Transferrins, e.g. lactoferrins, ovotransferrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dispersion Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2009249812A 2008-05-19 2009-05-13 Perfluorcarbon nanoemulsions with endocytosis enhancing surface for gene-transfer Ceased AU2009249812B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP08156434A EP2123256A1 (en) 2008-05-19 2008-05-19 Perfluorcarbon nanoemulsions with endocytosis enhancing surface for gene-transfer
EP08156434.6 2008-05-19
PCT/EP2009/055779 WO2009141257A1 (en) 2008-05-19 2009-05-13 Perfluorcarbon nanoemulsions with endocytosis enhancing surface for gene-transfer

Publications (2)

Publication Number Publication Date
AU2009249812A1 AU2009249812A1 (en) 2009-11-26
AU2009249812B2 true AU2009249812B2 (en) 2013-08-22

Family

ID=39869983

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2009249812A Ceased AU2009249812B2 (en) 2008-05-19 2009-05-13 Perfluorcarbon nanoemulsions with endocytosis enhancing surface for gene-transfer

Country Status (14)

Country Link
US (1) US9616131B2 (enExample)
EP (3) EP2123256A1 (enExample)
JP (1) JP5546534B2 (enExample)
CN (2) CN102847170B (enExample)
AU (1) AU2009249812B2 (enExample)
CA (1) CA2725513C (enExample)
DK (2) DK2510921T3 (enExample)
ES (2) ES2391375T3 (enExample)
HU (1) HUE035320T2 (enExample)
IL (1) IL209205A (enExample)
NZ (1) NZ589417A (enExample)
PL (2) PL2285349T3 (enExample)
WO (1) WO2009141257A1 (enExample)
ZA (1) ZA201008274B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2123256A1 (en) 2008-05-19 2009-11-25 Ruhr-Universität Bochum Perfluorcarbon nanoemulsions with endocytosis enhancing surface for gene-transfer
CN103764169B (zh) * 2011-03-31 2017-06-13 康斯坦策·沙费尔 用于非病毒转移核酸的全氟化化合物
CN103251980B (zh) * 2013-05-17 2014-07-02 中国人民解放军第四军医大学 全氟三丁胺与纤维蛋白水凝胶复合的神经导管制备方法
CN103263695B (zh) * 2013-05-17 2014-10-29 中国人民解放军第四军医大学 全氟三乙胺乳液与种子细胞复合的神经导管制备方法
EP2853595A1 (en) * 2013-09-30 2015-04-01 Soluventis GmbH NOTCH 1 specific siRNA molecules
EP3549609A4 (en) * 2016-12-01 2020-07-29 Saitama University ENDOCYTOSIS ACTIVATOR FOR DRUG DELIVERY SYSTEMS
WO2025080939A1 (en) 2023-10-13 2025-04-17 Ultragenyx Pharmaceutical, Inc. Compositions and methods for treating conditions associated with cartilage oligomeric matrix protein (comp) mutations
WO2025128853A2 (en) 2023-12-13 2025-06-19 Ultragenyx Pharmaceutical Inc. Compositions and methods for treating conditions associated with ube3a overexpression

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996040057A2 (en) * 1995-06-07 1996-12-19 Alliance Pharmaceutical Corp. Reverse fluorocarbon emulsion compositions for drug delivery

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6050578B2 (ja) 1981-12-25 1985-11-09 日本スチレンペ−パ−株式会社 合成樹脂発泡体の製造法
FR2720943B1 (fr) 1994-06-09 1996-08-23 Applic Transferts Technolo Emulsions inverses stables à forte concentration en composé(s) fluoré(s) et leur utilisation pour l'administration pulmonaire de médicaments et pour la fabrication d'émulsions multiples.
US6071890A (en) 1994-12-09 2000-06-06 Genzyme Corporation Organ-specific targeting of cationic amphiphile/DNA complexes for gene therapy
US5667809A (en) * 1995-06-07 1997-09-16 Alliance Pharmaceutical Corp. Continuous fluorochemical microdispersions for the delivery of lipophilic pharmaceutical agents
JP2001002592A (ja) * 1999-06-18 2001-01-09 Dai Ichi Seiyaku Co Ltd 遺伝子導入用組成物
KR20080046750A (ko) 2000-03-24 2008-05-27 바이오스피어 메디칼 인코포레이티드 능동 색전화용 미소구
US20020155084A1 (en) * 2000-06-02 2002-10-24 The Regents Of The University Of The Michigan Nanoemulsion formulations
KR20030039363A (ko) * 2000-07-20 2003-05-17 오뜨끄리또에 악찌오네르노에 오브셰스뜨보 나우취노-쁘로이즈보드스뜨벤나야 피르마 "뻬르프또란" 의료용 퍼플루오르 유기화합물의 유제 및 그 제조방법 및그것을 이용한 질병 치료 및 예방방법
ATE392812T1 (de) 2001-07-10 2008-05-15 Sonogene Llc Verbesserung der transfektion von dna in die leber
US20040115159A1 (en) 2002-03-29 2004-06-17 Tadlock Charles C Novel nanoemulsions
GB0408164D0 (en) 2004-04-13 2004-05-19 Immune Targeting Systems Ltd Antigen delivery vectors and constructs
US20070184076A1 (en) 2006-02-07 2007-08-09 Unger Evan C Liquid-filled nanodroplets for anti-cancer therapy
EP1844772A1 (en) 2006-04-06 2007-10-17 Polyplus-Transfection SA Compositions for transfection of oligonucleotides active for gene silencing and their biological and therapeutical applications
EP2123256A1 (en) 2008-05-19 2009-11-25 Ruhr-Universität Bochum Perfluorcarbon nanoemulsions with endocytosis enhancing surface for gene-transfer

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996040057A2 (en) * 1995-06-07 1996-12-19 Alliance Pharmaceutical Corp. Reverse fluorocarbon emulsion compositions for drug delivery

Also Published As

Publication number Publication date
CN102112109B (zh) 2016-10-12
CN102847170B (zh) 2016-03-16
EP2510921B1 (en) 2017-07-12
HK1159479A1 (zh) 2012-08-03
DK2285349T3 (da) 2012-10-22
CN102847170A (zh) 2013-01-02
EP2285349A1 (en) 2011-02-23
CA2725513C (en) 2013-07-02
WO2009141257A1 (en) 2009-11-26
US9616131B2 (en) 2017-04-11
PL2285349T3 (pl) 2012-12-31
DK2510921T3 (en) 2017-10-23
CN102112109A (zh) 2011-06-29
AU2009249812A1 (en) 2009-11-26
EP2510921A1 (en) 2012-10-17
NZ589417A (en) 2012-03-30
HK1179533A1 (zh) 2013-10-04
IL209205A (en) 2015-08-31
ES2391375T3 (es) 2012-11-23
CA2725513A1 (en) 2009-11-26
HUE035320T2 (en) 2018-05-02
EP2123256A1 (en) 2009-11-25
EP2285349B1 (en) 2012-07-11
IL209205A0 (en) 2011-01-31
ES2642316T3 (es) 2017-11-16
JP2011520936A (ja) 2011-07-21
US20110091561A1 (en) 2011-04-21
JP5546534B2 (ja) 2014-07-09
ZA201008274B (en) 2012-02-29
PL2510921T3 (pl) 2017-12-29

Similar Documents

Publication Publication Date Title
AU2009249812B2 (en) Perfluorcarbon nanoemulsions with endocytosis enhancing surface for gene-transfer
Gupta et al. Polymeric micelles and nanoemulsions as drug carriers: Therapeutic efficacy, toxicity, and drug resistance
JP7515914B2 (ja) 生体内薬物伝達のための脂質ナノ粒子およびその用途
Gao et al. H 2 O 2-responsive and plaque-penetrating nanoplatform for mTOR gene silencing with robust anti-atherosclerosis efficacy
ES2711669A1 (es) Sistemas de liberacion de farmacos de acido polisialico y metodos
CN102824647A (zh) 基于小核酸药物成骨治疗的骨靶向递送系统及其制备方法
Guo et al. Turning a water and oil insoluble cisplatin derivative into a nanoparticle formulation for cancer therapy
KR20220092363A (ko) 지질 나노입자를 포함하는 암 예방 또는 치료용 조성물
Qian et al. Low density lipoprotein mimic nanoparticles composed of amphipathic hybrid peptides and lipids for tumor-targeted delivery of paclitaxel
US11213573B2 (en) Particles comprising surfactant protein B and one or more lipids
Nguyen et al. A Review on Nanosystem-Based Delivery of Tofacitinib for Enhanced Treatment of Autoimmune Diseases and Inflammation
Muñoz-Correa et al. Evaluation of a mucoadhesive auto-nanoemulsifying drug delivery system (SNEDDS) for oral insulin administration
Yamamoto et al. Failure of active targeting by a cholesterol-anchored ligand and improvement by altering the lipid composition to prevent ligand desorption
HK1159479B (en) Perfluorcarbon nanoemulsions with endocytosis enhancing surface for gene-transfer
HK1179533B (en) Perfluorcarbon nanoemulsions with endocytosis enhancing surface for gene-transfer
CN117338948A (zh) 一种ace2特异性结合肽修饰的递药系统及其制备方法和应用
CN117241836A (zh) 包含脂质纳米颗粒的用于预防或治疗癌症的组合物
JP2024500515A (ja) 脂質ナノ粒子を含む癌の予防または治療用組成物
Cai et al. Reverse Lipid Droplet Function for Hepatocellular Carcinoma Immunotherapy
Huang Functionalized Lipid Nanoparticles Show Efficacy in Glioma Animal Models
EP4540392A1 (en) Targeted nanomedicine for treating fibrotic lung disorders
CN115252591A (zh) Dmdd在制备抗乳腺癌药物方面的应用以及一种用dmdd制备的癌症靶向药物

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired